JAKARTA - The state-owned pharmaceutical company, PT Indofarma Tbk, recorded net sales of Rp. 849.32 billion in the first semester of 2021. This achievement rose 90 percent compared to the same period in 2020 of Rp. 447.29 billion.
The company with the stock code INAF managed to increase its sales thanks to the sales of medical devices and medicines. This is in accordance with Indofarma's management turn around strategy.
INAF also recorded a profit attributable to owners of the parent entity of Rp977.78 million in the first semester of 2021. Whereas in the same period the previous year, Indofarma recorded a loss of Rp4.66 billion.
Indofarma President Director Arief Pramuhanto said, operationally, the company has managed to improve performance so that it is able to get EBITDA in the first semester of 2021 of Rp. 187 billion compared to EBITDA in the same period in the previous year of Rp. 24 billion, or grew by 685 percent.
"The company's liabilities increased by 9 percent from the original Rp1.38 trillion to Rp1.51 trillion in the first semester of 2021. The company's assets also increased 7 percent from Rp1.82 trillion to Rp1.95 trillion," said Arief in his official statement, quoted Monday 2 August.
With the application of PSAK 71 accounting policy in 2021, Indofarma has provided an allowance for impairment of receivables amounting to Rp110.54 billion. This is part of the aspect of compliance with PSAK 71 regulations and the company's prudent actions.
Not to forget, INAF is committed to continuing to assist the government's efforts in accelerating the handling of the COVID-19 pandemic by providing pharmaceutical products and medical devices, as well as health services.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
